Yeah, Jakafi has side effects. TBH I don't know how frequent those side effects manifest, but it modulates haematopoiesis so it will of course have risks related to infection, platelet function, etc.
MSCs currently claim to have no side effects, though that would literally be a first for any therapeutic so it's tough to assess. But they would have to list a warning about these being blood derived products, so risks of anaphylaxis and risk of BBV I would think would be on their sheet, despite likely a low risk.
If MSCs do indeed modulate systemic inflammation, it's very unlikely they don't make someone more infection prone, but either their mechanism is so different from any other compound used for this in the past, or it hasn't been used on a large enough cohort yet for this side effect to manifest.
TLDR: Obviously something without side effects is preferred to something with no side effects. But there is a saying in the medical community that a drug with no side effects is a drug with no effects.
The trials do show REM-Ls efficacy in this cohort seems pretty similar to Jakafi though, so that's promising.
GLTAH
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-197
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |